PHIO · Phio Pharmaceuticals Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.79M | - | $1.18M | $1.07M | $886.0K | - | $644.0K | $866.0K | $1.15M | - |
| SG&A | $1.37M | - | $1.32M | $1.24M | $986.0K | - | $946.0K | $1.05M | $1.06M | - |
| Total Operating Expenses | $4.17M | - | $2.50M | $2.31M | $1.87M | - | $1.59M | $1.91M | $2.21M | - |
| D&A | $1.0K | - | - | - | $0 | - | - | - | $1.0K | - |
| Operating Income | ($4.17M) | - | ($2.50M) | ($2.31M) | ($1.87M) | - | ($1.59M) | ($1.91M) | ($2.21M) | - |
| Interest Expense | - | - | - | - | ($53.0K) | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.00M) | - | ($2.39M) | ($2.17M) | ($1.77M) | - | ($1.52M) | ($1.85M) | ($2.15M) | - |
| EPS - Basic | ($0.34) | - | ($0.44) | ($0.45) | ($0.41) | - | ($1.54) | ($3.62) | ($4.23) | - |
| EPS - Diluted | - | - | - | ($0.45) | ($0.41) | - | ($1.54) | ($3.62) | ($4.23) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M | $8.41M | $4.70M | $6.47M | $8.49M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $260.0K | $435.0K | $516.0K | $235.0K | $427.0K | $253.0K | $184.0K | $335.0K | $320.0K | $657.0K |
| Current Assets | $17.40M | $21.48M | $11.49M | $11.29M | $13.44M | $5.74M | $5.86M | $5.29M | $6.85M | $9.32M |
| Total Assets | $17.41M | $21.49M | $11.51M | $11.30M | $13.44M | $5.74M | $5.87M | $5.30M | $6.85M | $9.36M |
| Current Liabilities | - | - | - | $1.21M | $1.27M | $1.01M | $919.0K | $1.52M | $1.25M | $1.63M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $950.0K | $1.34M | $1.67M | $1.21M | $1.27M | $1.01M | - | - | - | $1.63M |
| Stockholders' Equity | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M | $4.95M | $3.77M | $5.60M | $7.73M |
| Retained Earnings | ($159.06M) | ($155.05M) | ($152.68M) | ($150.29M) | ($148.13M) | ($146.36M) | ($144.73M) | ($143.21M) | ($141.36M) | ($139.21M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.00M) | - | - | - | ($1.27M) | - | - | - | ($2.01M) | - |
| Investing Cash Flow | $3.0K | - | - | - | $0 | - | - | - | - | - |
| Financing Cash Flow | $0 | - | - | - | $9.17M | - | - | - | ($4.0K) | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($4.00M) | - | - | - | ($1.27M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.00 | - | - | - | 0.72 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.0% | - | -20.8% | -19.2% | -13.2% | - | -26.0% | -34.9% | -31.4% | - |
| Return on equity | -24.3% | - | -24.3% | -21.5% | -14.5% | - | -30.8% | -48.9% | -38.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | 9.36 | 10.58 | 5.65 | 6.38 | 3.47 | 5.48 | 5.71 |
| Quick ratio | - | - | - | 9.36 | 10.58 | 5.65 | 6.38 | 3.47 | 5.48 | 5.71 |
| Cash ratio | - | - | - | 8.93 | 10.46 | 5.30 | 9.15 | 3.08 | 5.18 | 5.20 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | 35.3x | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.07 | 1.17 | 1.12 | 1.10 | 1.21 | 1.19 | 1.40 | 1.22 | 1.21 |
| Liabilities / Assets | 0.05 | 0.06 | 0.14 | 0.11 | 0.09 | 0.18 | - | - | - | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 1.1x | 0.5x | - | 0.7x | 0.8x | 5.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -122.6% | - | -57.5% | -20.6% | 15.3% | - | 42.7% | 24.9% | 38.7% | - |
| Net income growth (YoY) | -126.3% | - | -57.0% | -17.3% | 17.9% | - | 45.2% | 27.6% | 40.2% | - |
| EPS growth (YoY) | - | - | - | 87.6% | 90.3% | - | -35.1% | -146.3% | -34.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -214.0% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 35.3% | 326.6% | 98.9% | 167.6% | 117.2% | -38.9% | -31.4% | -61.9% | -23.3% | -28.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Phio Pharmaceuticals Corp. against the 5 most active filers in the same SIC group.